Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 22, 2025

RBE

RRID:CVCL_4896
Type: Cell Line

Proper Citation

(RRID:CVCL_4896)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4896

Proper Citation: (RRID:CVCL_4896)

Sex: Female

Defining Citation: PMID:9358283, PMID:15767549, PMID:27231123, PMID:31077409, PMID:35640676, PMID:39026794

Comments: Omics: Transcriptome analysis by microarray., Omics: Deep exome analysis., Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: Biliary tract cancer cell line atlas.

Category: Cancer cell line

Name: RBE

Cross References: CLO:CLO_0050848, BioSample:SAMN03472125, cancercelllines:CVCL_4896, CCRID:1101HUM-PUMC000675, CCRID:3101HUMTCHu179, Cell_Model_Passport:SIDM01850, CLS:305019, Cosmic:1187341, Cosmic:1571785, Cosmic:2629289, DepMap:ACH-001856, KCB:KCB 2014049YJ, RCB:RCB1292, Wikidata:Q54949330

ID: CVCL_4896

Record Creation Time: 20250131T202425+0000

Record Last Update: 20250131T204316+0000

Ratings and Alerts

No rating or validation information has been found for RBE.

No alerts have been found for RBE.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Li J, et al. (2024) Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1. Pharmaceutical biology, 62(1), 314.

Chen T, et al. (2024) S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathway. Cancer letters, 587, 216709.

Myint KZ, et al. (2024) Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals (Basel, Switzerland), 17(2).

Ratanabunyong S, et al. (2024) Exploring the apoptotic effects of sericin on HCT116 cells through comprehensive nanostring transcriptomics and proteomics analysis. Scientific reports, 14(1), 2366.

Zhang C, et al. (2024) Re-evaluation of the relationship between PrPc expression and patient prognosis in primary esophageal squamous cell carcinoma and primary hepatocellular carcinoma. Scientific reports, 14(1), 31122.

Hu J, et al. (2024) Modulating PCGF4/BMI1 Stability Is an Efficient Metastasis-Regulatory Strategy Used by Distinct Subtypes of Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma. The American journal of pathology, 194(7), 1388.

Noronha KJ, et al. (2024) NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. Molecular cancer research : MCR, 22(10), 973.

Alva-Ruiz R, et al. (2024) YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. FEBS open bio, 14(11), 1873.

Mohan A, et al. (2023) Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04). Clinical

cancer research : an official journal of the American Association for Cancer Research, 29(13), 2394.

Jamnongsong S, et al. (2022) Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. iScience, 25(10), 105182.

Dong L, et al. (2022) Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer cell, 40(1), 70.

Liu Z, et al. (2022) Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma. Oncology reports, 48(3).

Liu W, et al. (2022) Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional polymorphisms on biliary tract cancer risk. International journal of cancer, 150(11), 1825.

Chen S, et al. (2022) Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts. Oncology letters, 24(1), 236.

Hao X, et al. (2021) STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. iScience, 24(11), 103223.